iTeos Therapeutics, Inc. - Common Stock (NQ:ITOS)

10.15 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iTeos Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS

August 19, 2025

From Kahn Swick & Foti, LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, VBTX, TTNP on Behalf of Shareholders July 31, 2025

July 31, 2025

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, SPTN on Behalf of Shareholders

July 30, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: iTeos Therapeutics, Inc. (Nasdaq - ITOS), ZimVie Inc. (Nasdaq - ZIMV), PharmChem, Inc. (OTC - PCHM), NV5 Global, Inc. (Nasdaq - NVEE)

July 30, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, CIO, SNV on Behalf of Shareholders

July 26, 2025

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, TASK, OLO on Behalf of Shareholders

July 23, 2025

From Halper Sadeh LLC

Via GlobeNewswire

ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS

July 22, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders

July 21, 2025

From Halper Sadeh LLC

Via GlobeNewswire

ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders

July 21, 2025

From Halper Sadeh LLC

Via Business Wire

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

July 21, 2025

From iTeos Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 28, 2025

Via Benzinga

iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’ ↗

May 28, 2025

The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended.

Via Stocktwits

Topics Intellectual Property

These stocks are gapping in today's session ↗

May 28, 2025

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗

May 28, 2025

Via Benzinga

iTeos Therapeutics Announces Its Intention to Wind Down Operations

May 28, 2025

From iTeos Therapeutics Inc.

Via GlobeNewswire

This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday ↗

May 14, 2025

Via Benzinga

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 14, 2025

Via Benzinga

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile ↗

May 13, 2025

iTeos ends belrestotug program with GSK after Phase 2 trial fails to meet key survival goals; company explores strategic options to boost shareholder value.

Via Benzinga

iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish ↗

May 13, 2025

The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer.

Via Stocktwits

Topics Government

iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

May 13, 2025

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

April 28, 2025

From iTeos Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 03, 2025

Via Benzinga

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

March 25, 2025

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 05, 2025

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

January 10, 2025

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 08, 2025

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

December 12, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos to Participate in Upcoming Investor Conferences

November 26, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 12, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

October 24, 2024

From iTeos Therapeutics Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.